# Eric Murphy

> Eric Murphy, Ph.D., is a San Diego scientist and serial company founder. He co-founded Alterome Therapeutics, Kinnate Biopharma and Fount Therapeutics, and currently serves as CEO, co-founder and director of Sidewinder Therapeutics. His career spans academic research, industrial research and company leadership, with public commitments to mentoring and community involvement.

- **Role:** Chief Executive Officer, Co-Founder & Director at Sidewinder Therapeutics
- **Organizations:** Sidewinder Therapeutics, Alterome Therapeutics, Kinnate Biopharma, Fount Therapeutics, Crown Bioscience, Samumed, Genomics Institute of the Novartis Research Foundation, University of California, San Diego, The Scripps Research Institute, Life Science Cares
- **Education:** B.S. in Biochemistry, University of California, Davis, Ph.D. in Biological Sciences, University of California, Irvine, Postdoctoral fellowship with David Cheresh, The Scripps Research Institute
- **Known for:** Co-founded Fount Therapeutics, Kinnate Biopharma, Alterome Therapeutics and Sidewinder Therapeutics., Recognized among Goldman Sachs’ 100 entrepreneurs at the 2024 Builders and Innovators Summit., Led Alterome as CEO during its January 2022 launch and April 2024 Series B announcement.

## Career timeline

- **2003-2005** — Postdoctoral fellow at Scripps.
- **2005-2011** — Research appointments at UC San Diego.
- **2011-2014** — Research Investigator at Novartis GNF.
- **2014-2015** — Director, Discovery Biology at Samumed.
- **2016-2017** — Global research strategy and external innovation leadership at Crown Bioscience.
- **2018** — Co-founder and Chief Scientific Officer of Kinnate; board service began in January.
- **2022** — Alterome publicly launched with Murphy as co-founder, CEO and CSO and $64 million Series A financing.
- **2023** — Sidewinder founded with OrbiMed backing; Murphy is a co-founder.
- **2024** — Alterome announced $132 million Series B; Murphy received Goldman Sachs recognition in October.
- **2025** — Alterome named Jung Choi CEO in April; Sidewinder identifies Murphy as CEO, co-founder and director.
- **2026** — Sidewinder announced $137 million Series B in April.

## Achievements

- Co-founded Fount Therapeutics, Kinnate Biopharma, Alterome Therapeutics and Sidewinder Therapeutics.
- Recognized among Goldman Sachs’ 100 entrepreneurs at the 2024 Builders and Innovators Summit.
- Led Alterome as CEO during its January 2022 launch and April 2024 Series B announcement.
- CEO of Sidewinder when it announced its $137 million Series B in April 2026.

## Latest updates

- **2026-04** — Sidewinder announced a $137 million Series B co-led by Frazier Life Sciences and Novartis Venture Fund; total company funding reached $162 million.
- **2026-01** — Participated in a Longwood leaders panel in San Francisco on the funding environment and innovation.
- **2026-01** — Sidewinder announced a licensing agreement with Lonza’s Synaffix.

## Links

- Website: https://sidewinderbio.com/team/eric-murphy-phd/
- LinkedIn: https://www.linkedin.com/in/murphness/

---

Profile page: https://yespress.io/eric-murphy
Published by YesPress — https://yespress.io
Last updated: 2026-10-08